Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia

Pere Barba; Izaskun Elorza

doi:10.1016/j.medcli.2019.01.017

Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia

Pere Barba, Izaskun Elorza

Department of Medicine

Research output: Contribution to journal › Review article › Research › peer-review

Abstract

© 2019 Elsevier España, S.L.U. Immunotherapy is changing the treatment of acute lymphoblastic leukaemia (ALL) in adults and children. However, regardless of these new therapies, allogeneic hematopoietic cell transplantation (allo-HCT) still play a key role in the treatment of ALL, although it is uncertain how these new therapies will impact on the transplant procedure and indications. This article reviews the indications of allo-HCT for children and adults diagnosed with ALL, the different sources and conditioning regimens for transplantation as well as the role of measurable residual diseases pre- and post-HCT in the era of the new therapies for ALL.

Original language	English
Pages (from-to)	28-34
Journal	Medicina Clinica
Volume	153
Issue number	1
DOIs	https://doi.org/10.1016/j.medcli.2019.01.017
Publication status	Published - 5 Jul 2019

Keywords

Acute lymphoblastic leukaemia
Allogeneic transplantation
CAR-T
Immunotherapy
Monoclonal antibodies

Access to Document

10.1016/j.medcli.2019.01.017

Cite this

@article{b5bba1e6329c4b159f6ca6887f282ee9,

title = "Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia",

abstract = "{\textcopyright} 2019 Elsevier Espa{\~n}a, S.L.U. Immunotherapy is changing the treatment of acute lymphoblastic leukaemia (ALL) in adults and children. However, regardless of these new therapies, allogeneic hematopoietic cell transplantation (allo-HCT) still play a key role in the treatment of ALL, although it is uncertain how these new therapies will impact on the transplant procedure and indications. This article reviews the indications of allo-HCT for children and adults diagnosed with ALL, the different sources and conditioning regimens for transplantation as well as the role of measurable residual diseases pre- and post-HCT in the era of the new therapies for ALL.",

keywords = "Acute lymphoblastic leukaemia, Allogeneic transplantation, CAR-T, Immunotherapy, Monoclonal antibodies",

author = "Pere Barba and Izaskun Elorza",

year = "2019",

month = jul,

day = "5",

doi = "10.1016/j.medcli.2019.01.017",

language = "English",

volume = "153",

pages = "28--34",

journal = "Medicina Clinica",

issn = "0025-7753",

number = "1",

}

TY - JOUR

T1 - Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia

AU - Barba, Pere

AU - Elorza, Izaskun

PY - 2019/7/5

Y1 - 2019/7/5

N2 - © 2019 Elsevier España, S.L.U. Immunotherapy is changing the treatment of acute lymphoblastic leukaemia (ALL) in adults and children. However, regardless of these new therapies, allogeneic hematopoietic cell transplantation (allo-HCT) still play a key role in the treatment of ALL, although it is uncertain how these new therapies will impact on the transplant procedure and indications. This article reviews the indications of allo-HCT for children and adults diagnosed with ALL, the different sources and conditioning regimens for transplantation as well as the role of measurable residual diseases pre- and post-HCT in the era of the new therapies for ALL.

AB - © 2019 Elsevier España, S.L.U. Immunotherapy is changing the treatment of acute lymphoblastic leukaemia (ALL) in adults and children. However, regardless of these new therapies, allogeneic hematopoietic cell transplantation (allo-HCT) still play a key role in the treatment of ALL, although it is uncertain how these new therapies will impact on the transplant procedure and indications. This article reviews the indications of allo-HCT for children and adults diagnosed with ALL, the different sources and conditioning regimens for transplantation as well as the role of measurable residual diseases pre- and post-HCT in the era of the new therapies for ALL.

KW - Acute lymphoblastic leukaemia

KW - Allogeneic transplantation

KW - CAR-T

KW - Immunotherapy

KW - Monoclonal antibodies

U2 - 10.1016/j.medcli.2019.01.017

DO - 10.1016/j.medcli.2019.01.017

M3 - Review article

C2 - 30857792

VL - 153

SP - 28

EP - 34

JO - Medicina Clinica

JF - Medicina Clinica

SN - 0025-7753

IS - 1

ER -

Allogeneic stem cell transplantation in the era of novel therapies for acute lymphoblastic leukaemia

Abstract

Keywords

Access to Document

Fingerprint

Cite this